Human Gene Therapy - April 2023 - 301

ENGINEERED HEPATOTROPIC NAB EVASIVE AAV3B VARIANT
301
24. Boutin S, Monteilhet V, Veron P, et al. Prevalence
of serum IgG and neutralizing factors against
adeno-associated virus (AAV) types 1, 2, 5, 6, 8,
and 9 in the healthy population: Implications for
gene therapy using AAV vectors. Hum Gene Ther
2010;21(6):704-712; doi: 10.1089/hum.2009.182
25. Qian R, Xiao B, Li J, et al. Directed evolution of
AAV serotype 5 for increased hepatocyte transduction
and retained low humoral seroreactivity.
Mol Ther Methods Clin Dev 2021;20:122-132; doi:
10.1016/j.omtm.2020.10.010
26. Brown HC, Doering CB, Herzog RW, et al. Development
of a clinical candidate AAV3 vector for
gene therapy of hemophilia B. Hum Gene Ther
2020;31(19-20):1114-1123; doi: 10.1089/
hum.2020.099
27. Batty P, Lillicrap D. Gene therapy for hemophilia:
Current status and laboratory consequences. Int J
Lab Hematol 2021;43(Suppl 1):117-123; doi:
10.1111/ijlh.13605
28. Long BR, Veron P, Kuranda K, et al. Early phase
clinical immunogenicity of valoctocogene roxaparvovec,
an AAV5-mediated gene therapy for
hemophilia A. Mol Ther 2021;29(2):597-610; doi:
10.1016/j.ymthe.2020.12.008
29. Perrin GQ, Herzog RW, Markusic DM. Update on
clinical gene therapy for hemophilia. Blood 2019;
133(5):407-414; doi: 10.1182/blood-2018-07820720
30.
Monahan PE, Negrier C, Tarantino M, et al.
Emerging immunogenicity and genotoxicity considerations
of adeno-associated virus vector gene
therapy for hemophilia. J Clin Med 2021;10(11):
2471; doi: 10.3390/jcm10112471
31. Santiago-Ortiz J, Ojala DS, Westesson O, et al.
AAV ancestral reconstruction library enables selection
of broadly infectious viral variants. Gene
Ther 2015;22(12):934-946; doi: 10.1038/
gt.2015.74
32. Gross DA, Tedesco N, Leborgne C, et al. Overcoming
the challenges imposed by humoral immunity
to AAV vectors to achieve safe and
efficient gene transfer in seropositive patients.
Front Immunol 2022;13:857276; doi: 10.3389/
fimmu.2022.857276
33. Asokan A, Schaffer DV, Samulski RJ. The AAV
vector toolkit: Poised at the clinical crossroads.
Mol Ther 2012;20(4):699-708; doi: 10.1038/
mt.2011.287
34. Lisowski L, Dane AP, Chu K, et al. Selection and
evaluation of clinically relevant AAV variants in a
xenograft liver model. Nature 2014;506(7488):
382-386; doi: 10.1038/nature12875
35. Biswas M, Marsic D, Li N, et al. Engineering and
in vitro selection of a novel AAV3B variant with
high hepatocyte tropism and reduced seroreactivity.
Mol Ther Methods Clin Dev 2020;19:
347-361; doi: 10.1016/j.omtm.2020.09.019
36. Marsic D, Govindasamy L, Currlin S, et al. Vector
design Tour de Force: integrating combinatorial
and rational approaches to derive novel adenoassociated
virus variants. Mol Ther 2014;22(11):
1900-1909; doi: 10.1038/mt.2014.139
37. Grimm D, Buning H. Small but increasingly mighty:
Latest advances in AAV vector research, design,
and evolution. Hum Gene Ther 2017;28(11):1075-
1086; doi: 10.1089/hum.2017.172
38. Bartel MA, Weinstein JR, Schaffer DV. Directed
evolution of novel adeno-associated viruses for
therapeutic gene delivery. Gene Ther 2012;19(6):
694-700; doi: 10.1038/gt.2012.20
39. Li W, Asokan A, Wu Z, et al. Engineering and
selection of shuffled AAV genomes: a new strategy
for producing targeted biological nanoparticles.
Mol Ther 2008;16(7):1252-1260; doi:
10.1038/mt.2008.100
40. Cabanes-Creus M, Navarro RG, Zhu E, et al. Novel
human liver-tropic AAV variants define transferable
domains that markedly enhance the human
tropism of AAV7 and AAV8. Mol Ther Methods
Clin Dev 2022;24:88-101; doi: 10.1016/
j.omtm.2021.11.011
41. Wang L, Bell P, Somanathan S, et al. Comparative
study of liver gene transfer with AAV vectors
based on natural and engineered AAV capsids.
Mol Ther 2015;23(12):1877-1887; doi: 10.1038/
mt.2015.179
42. Vercauteren K, Hoffman BE, Zolotukhin I, et al.
Superior in vivo transduction of human hepatocytes
using engineered AAV3 capsid. Mol Ther
2016;24(6):1042-1049; doi: 10.1038/mt.2016.61
43. Li S, Ling C, Zhong L, et al. Efficient and targeted
transduction of nonhuman primate liver with
systemically delivered optimized AAV3B vectors.
Mol Ther 2015;23(12):1867-1876; doi: 10.1038/
mt.2015.174
44. Ran G, Chen X, Xie Y, et al. Site-directed mutagenesis
improves the transduction efficiency of
capsid library-derived recombinant AAV vectors.
Mol Ther Methods Clin Dev 2020;17:545-555; doi:
10.1016/j.omtm.2020.03.007
45. Ito M, Takino N, Nomura T, et al. Engineered
adeno-associated virus 3 vector with reduced reactivity
to serum antibodies. Sci Rep 2021;11(1):
9322; doi: 10.1038/s41598-021-88614-9
46. Daniel HD, Kumar S, Kannangai R, et al. Prevalence
of adeno-associated virus 3 capsid binding
and neutralizing antibodies in healthy and
hemophilia B individuals from India. Hum Gene
Ther 2021;32(9-10):451-457; doi: 10.1089/
hum.2020.258
47. Ling C, Wang Y, Feng YL, et al. Prevalence of
neutralizing antibodies against liver-tropic adenoassociated
virus serotype vectors in 100 healthy
Chinese and its potential relation to body constitutions.
J Integr Med 2015;13(5):341-346; doi:
10.1016/S2095-4964(15)60200-X
48. Pei X, Shao W, Xing A, et al. Development of AAV
variants with human hepatocyte tropism and
neutralizing antibody escape capacity. Mol Ther
Methods Clin Dev 2020;18:259-268; doi: 10.1016/
j.omtm.2020.06.003
49. de Alencastro G, Pekrun K, Valdmanis P, et al.
Tracking adeno-associated virus capsid evolution
by high-throughput sequencing. Hum Gene Ther
2020;31(9-10):553-564;
doi:
hum.2019.339
50. Crosson SM, Dib P, Smith JK, et al. Helper-free
production of laboratory grade AAV and purification
by iodixanol density gradient centrifugation.
Mol Ther Methods Clin Dev 2018;10:1-7; doi:
10.1016/j.omtm.2018.05.001
51. Aurnhammer C, Haase M, Muether N, et al.
Universal real-time PCR for the detection and
quantification of adeno-associated virus serotype
2-derived inverted terminal repeat sequences.
Hum Gene Ther Methods 2012;23(1):18-28; doi:
10.1089/hgtb.2011.034
52. Bissig-Choisat B, Wang L, Legras X, et al. Development
and rescue of human familial hypercholesterolaemia
in a xenograft mouse model.
Nat Commun 2015;6:7339; doi: 10.1038/
ncomms8339
53. Zou C, Vercauteren KOA, Michailidis E, et al. Experimental
variables that affect human hepatocyte
AAV transduction in liver chimeric mice. Mol
Ther Methods Clin Dev 2020;18:189-198; doi:
10.1016/j.omtm.2020.05.033
54. Meliani A, Leborgne C, Triffault S, et al. Determination
of anti-adeno-associated virus vector
neutralizing antibody titer with an in vitro reporter
system. Hum Gene Ther Methods 2015;26(2):45-
53; doi: 10.1089/hgtb.2015.037
55. Michailidis E, Vercauteren K, Mancio-Silva L,
et al. Expansion, in vivo-ex vivo cycling, and genetic
manipulation of primary human hepatocytes.
Proc Natl Acad Sci U S A 2020;117(3):1678-1688;
doi: 10.1073/pnas.1919035117
56. Vanwolleghem T, Libbrecht L, Hansen BE, et al.
Factors determining successful engraftment of
hepatocytes and susceptibility to hepatitis B and
C virus infection in uPA-SCID mice. J Hepatol
2010;53(3):468-476;
j.jhep.2010.03.024
doi:
10.1016/
57. Kawahara T, Toso C, Douglas DN, et al. Factors
affecting hepatocyte isolation, engraftment, and
replication in an in vivo model. Liver Transpl 2010;
16(8):974-982; doi: 10.1002/lt.22099
58. Billerbeck E, Mommersteeg MC, Shlomai A,
et al. Humanized mice efficiently engrafted with
fetal hepatoblasts and syngeneic immune cells
develop human monocytes and NK cells. J Hepatol
2016;65(2):334-343; doi: 10.1016/
j.jhep.2016.04.022
59. Ling C, Wang Y, Zhang Y, et al. Selective in vivo
targeting of human liver tumors by optimized
AAV3 vectors in a murine xenograft model. Hum
Gene Ther 2014;25(12):1023-1034; doi: 10.1089/
hum.2014.099
60. Gao GP, Alvira MR, Wang L, et al. Novel adenoassociated
viruses from rhesus monkeys as vectors
for human gene therapy. Proc Natl Acad Sci
U S A 2002;99(18):11854-11859; doi: 10.1073/
pnas.182412299
10.1089/
Human Gene Therapy - April 2023

Table of Contents for the Digital Edition of Human Gene Therapy - April 2023
